Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PGF2α/LTB4 production inhibitor
Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF2α and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM). -
5-Lipoxygenase (5-LO) inhibitor
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation. -
leukotriene A4 hydrolase inhibitor
Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug. -
LTC4 inhibitor
Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2). -
Protein Kinase C Inhibitor/LTD4 Antagonist
LY 170198 is a potent protein kinase C inhibitor and LTD4 antagonist. This compound exhibits significant biological activity relevant to studies on tumor promotion, oncogene activation, and protein phosphorylation. Additionally, it is valuable for investigating feedback mechanisms in signal transduction pathways and cellular responses to growth factors, making it a useful tool for cancer research and related fields. -
LTB4 inhibitor
U-75302 is a potent inhibitor of leukotriene B4, developed as a pyridine analogue. This compound demonstrates significant anti-inflammatory activity, making it valuable for research into various inflammatory diseases. U-75302 can help elucidate the role of leukotriene B4 in pathophysiological processes, contributing to better understanding and potential therapeutic strategies in inflammation-related conditions. -
PGF2α/LTB4 Inhibitor
Darbufelone is a dual inhibitor of prostaglandin F2α (PGF2α) and leukotriene B4 (LTB4) production, primarily targeting the cyclooxygenase enzyme PGHS-2 with an IC50 of 0.19 μM, while showing markedly lower potency against PGHS-1 (IC50 of 20 μM). This compound is valuable for research focused on inflammation, pain modulation, and the role of eicosanoids in various pathological conditions. Its selective inhibition of PGF2α and LTB4 makes Darbufelone a useful tool for studying the intersection of these signaling pathways in cellular responses. -
FPR Inhibitor
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) acts as an inhibitor of N-formyl peptide receptors (FPR). This compound effectively reduces FMLP-induced release of peptide leukotrienes and disrupts the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids in a three-dimensional fibrin gel model, which simulates the conditions associated with proliferative diabetic retinopathy (PDR) and vascular endothelial growth factor (VEGF). Additionally, Boc-Phe-Leu-Phe-Leu-Phe counteracts the anti-inflammatory and antifibrotic effects of Ac2-26. It is suitable for applications in immunological research. -
LTB4 Inhibitor
Halometasone is a corticosteroid that functions as an inhibitor of leukotriene B4 (LTB4) synthesis. It exhibits anti-inflammatory properties by reducing LTB4 and thymic stromal lymphopoietin (TSLP) levels. Halometasone is widely utilized in research related to psoriasis and other eczematous skin disorders, providing insights into corticosteroid-mediated effects on inflammatory pathways. -
Leukotriene Synthesis Inhibitor
L-674573 is a quinoline compound that functions as a selective inhibitor of leukotriene synthesis. It effectively inhibits leukotriene production induced by Calcimycin and N-Formyl-Met-Leu-Phe, with IC50 values of 100 nM and 50 nM, respectively. L-674573 specifically targets and inhibits the translocation of 5-lipoxygenase, making it a valuable tool for research into inflammatory processes and leukotriene-related diseases. Its application is particularly relevant in studies aimed at understanding leukotriene signaling pathways and developing anti-inflammatory therapeutics. -
Leukotriene Inhibitor
Piriprost potassium is a potent leukotriene synthesis inhibitor. It effectively suppresses the release of leukotrienes and histamine in isolated porcine lung cells, exhibiting an IC50 of 0.11 μM. Additionally, Piriprost potassium enhances alkaline phosphatase (ALP) activity in cultured endometrial stromal cells, making it a useful tool for research in inflammation and reproductive biology. -
Leukotriene Formation Inhibitor
Pirodomast is a potent leukotriene formation inhibitor that targets the release of leukotriene D4 (LTD4) and thromboxane B2 in anaphylactic guinea pig lung tissues. With IC50 values of 3.9 μM for LTD4 and 1.9 μM for thromboxane B2, Pirodomast demonstrates significant inhibitory activity. This compound is valuable for research applications related to asthma and inflammatory responses, providing insights into leukotriene-mediated pathways in respiratory conditions. -
cPLA2α Inhibitor
ZPL-5212372 is a potent inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 7 nM. This compound efficiently reduces the release of key inflammatory mediators such as prostaglandin D2, cysteinyl leukotrienes, leukotriene B4, and thromboxane A2 from human lung cells. Research indicates that ZPL-5212372 effectively attenuates delayed bronchoconstriction and airway hyperresponsiveness in models of allergic inflammation. Consequently, it serves as a valuable tool for investigating mechanisms and potential therapies for asthma. -
Dual Enkephalinase Inhibitor
PL265 is a dual enkephalinase inhibitor that acts as a prodrug of PL254. It effectively inhibits both neutral endopeptidase (neprilysin) and aminopeptidase N, leading to increased local concentrations of enkephalins like Met-Enkephalin and Leu-Enkephalin. This action subsequently activates μ and δ opioid receptors, resulting in a potent analgesic effect. Additionally, PL265's inhibition of leukotriene A4 hydrolase (LTA4H) may further enhance its anti-inflammatory properties by reducing the production of leukotriene B4 (LTB4). This reagent is particularly valuable in non-addictive chronic pain research. -
5-1ipoxygenase Inhibitor/Leukotriene D4 Antagonist
WAY-126299A is an orally active dual inhibitor of 5-lipoxygenase, demonstrating an IC50 of 12.2 μM, and serves as a leukotriene D4 antagonist with a pKB of 6.4. This compound effectively inhibits antigen-induced leukotriene-dependent bronchoconstriction. WAY-126299A is valuable in research related to asthma and other inflammatory conditions where leukotriene signaling plays a critical role. -
LTE4 Inhibitor
LY 245769 is a leukotriene E4 (LTE4) inhibitor that functions as an omega-trifluoro analog. It exhibits inhibitory activity by interfering with the omega-oxidation of N-acetyl-LTE4 and leukotriene B4 (LTB4), with an IC50 value of 4 μM. This compound is essential for research on inflammatory processes and bronchoconstriction, contributing to the understanding of leukotriene signaling pathways and their role in respiratory diseases. -
MRP1 Inhibitor
LY329146 is a selective inhibitor of multidrug resistance protein 1 (MRP1). It effectively inhibits the transport of leukotriene C4 (LTC4) with an IC50 of 0.8 μM. This compound is valuable for studies exploring multidrug resistance mechanisms and may have applications in enhancing the efficacy of chemotherapy in resistant cancer cells. -
Leukotriene Receptor Inhibitor
12(S)-HEPE is a monohydroxy fatty acid that acts as a leukotriene receptor inhibitor. It is synthesized from eicosapentaenoic acid (EPA) through the action of 12-lipoxygenase (12-LO). In unstimulated neutrophils, 12(S)-HEPE is metabolized to 12(S),20-diHEPE, while stimulated neutrophils generate 5(S),12(S)-HEPE via the 5-lipoxygenase pathway. Its competitive inhibition of arachidonic acid as a substrate for 5-lipoxygenase in leukotriene formation supports its potential anti-inflammatory effects associated with omega-3 fatty acids. -
LTA4H Inhibitor
JNJ-40929837 is a selective and orally active inhibitor of leukotriene A4 hydrolase (LTA4H). This compound effectively inhibits aminopeptidase activity, resulting in the accumulation of Pro-Gly-Pro in serum. JNJ-40929837 is primarily utilized in asthma research to explore its potential therapeutic effects and mechanisms of action related to inflammatory responses. -
Leukotriene Inhibitor
SCH 40120 is a potent leukotriene inhibitor that exhibits significant anti-inflammatory properties. This compound effectively suppresses T cell proliferation as well as both antigen-specific and polyclonal antibody responses in vitro. SCH 40120 also diminishes edematous responses and inhibits the recruitment of circulating neutrophils to inflamed tissues, making it a valuable tool in research related to anti-psoriatic agents. -
LTA4H Inhibitor
JNJ-40929837 succinate is a selective and orally active inhibitor of leukotriene A4 hydrolase (LTA4H). This compound effectively inhibits aminopeptidase activity, leading to the accumulation of Pro-Gly-Pro in serum. JNJ-40929837 succinate is particularly relevant for asthma research, providing a valuable tool for investigating inflammatory pathways and potential therapeutic interventions in respiratory conditions. -
Leukotriene Receptor Inhibitor
(R)-Ontazolast is a potent leukotriene receptor inhibitor that effectively blocks leukotriene biosynthesis. It demonstrates a remarkable IC50 value of 0.001 µM in human polymorphonuclear leukocytes, inhibiting the release of arachidonic acid. This compound is valuable for research applications related to inflammation and immune response modulation. -
Leukotriene B4 Inhibitor
Chamazulene is a natural compound that acts as an inhibitor of leukotriene B4 formation. Its antioxidant properties contribute to modulating inflammatory responses, making it relevant for research in inflammation and immune response studies. Chamazulene is particularly useful in exploring pathways related to leukotriene signaling and its role in various pathologies. -
Leukotriene Inhibitor
FK-664 is a potent leukotriene inhibitor that enhances ventricular contractility and reduces the time to peak tension in cardiac cells. In canine models of heart failure, FK-664 has been shown to decrease mean circulating pressure (MCP), indicating its potential therapeutic effects. This compound is valuable for research focused on cardiovascular diseases, particularly heart failure, and its underlying mechanisms. -
Leukotriene Receptor/FLAP Inhibitor
(S)-Veliflapon is a potent inhibitor of leukotriene biosynthesis targeting the 5-lipoxygenase activating protein (FLAP). It effectively inhibits the formation of leukotriene B4 (LTB4) in rat, mouse, and human leukocytes with IC50 values of 0.026 µM, 0.039 µM, and 0.22 µM, respectively. Additionally, (S)-Veliflapon demonstrates enantioselectivity in human whole blood, making it a valuable reagent for research in inflammation and related biological processes. -
Leukotriene Biosynthesis Inhibitor
L-691678 is an inhibitor of leukotriene biosynthesis that selectively binds to the 5-lipoxygenase-activating protein (FLAP). This compound disrupts leukotriene production, making it a valuable tool for investigating leukotriene-associated pathologies, including allergic responses, asthma, and inflammatory conditions. Its ability to modulate leukotriene levels provides insights into their role in various biological processes and disease mechanisms. -
Leukotriene Biosynthesis Inhibitor
ABT-080 is an orally active inhibitor of leukotriene biosynthesis, specifically targeting the pathways responsible for the production of LTB4 and LTC4. This compound effectively prevents bronchoconstriction, making it valuable for research into asthma and related inflammatory conditions. By selectively inhibiting leukotriene synthesis without affecting PGH2 biosynthesis, ABT-080 provides a critical tool for studying the role of leukotrienes in respiratory diseases. -
LTB4 Inhibitor
Ontazolast is a potent inhibitor of leukotriene B4 (LTB4) biosynthesis, making it a valuable tool for studying inflammatory pathways. Its primary mechanism targets the LTB4 synthesis pathway, which is associated with various inflammatory conditions. Ontazolast is particularly relevant in research applications focused on asthma and related respiratory disorders. -
Leukotriene Receptor Inhibitor
Bunaprolast is a potent leukotriene receptor inhibitor that effectively reduces LTB4 production in human whole blood. Additionally, it demonstrates significant inhibition of lipoxygenase activity and TXB2 release. This compound is valuable for research applications related to inflammatory diseases and respiratory conditions. -
Leukotriene Receptor Inhibitor
LTB4-IN-1 is a selective leukotriene receptor inhibitor, effectively blocking leukotriene B4 synthesis with an IC50 of 70 nM. This compound serves as a valuable tool for research in inflammation and immune response, potentially aiding in the investigation of leukotriene-mediated pathophysiological conditions. Its application can extend to studies focused on cellular signaling and therapeutic interventions targeting leukotriene pathways.
